Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer's Patients at AAIC 2026
核心洞察
Alzheon will present nine posters on valiltramiprosate at AAIC 2026, featuring expanded Phase 3 APOLLOE4 and Phase 2 trial analyses with new neurovascular protection and DTI imaging evidence.
The Phase 3 trial did not meet its primary endpoint, but pre-specified MCI subgroup analyses showed clinically meaningful cognitive and brain volume benefits alongside lower ARIA rates versus placebo.
Long-term extension data through up to four years demonstrated a favorable safety profile with no symptomatic ARIA-E or ARIA-H observed in APOE4 (搜索)/4 and APOE3/4 carriers.
Alzheon, Inc., a clinical-stage biopharmaceutical company, announced it will present nine posters on its lead investigational therapy, valiltramiprosate (ALZ-801), at the 2026 Alzheimer's Association International Conference (AAIC) in London, United Kingdom. The presentations feature expanded analyses from the Phase 3 APOLLOE4 and Phase 2 biomarker trials and their long-term extensions, including new evidence of neurovascular protection, diffusion tensor imaging (DTI) and volumetric MRI (vMRI) correlations with clinical outcomes, sustained long-term efficacy and safety, and a quantitative systems pharmacology (QSP) analysis evaluating valiltramiprosate as a potential oral maintenance therapy following anti-amyloid antibody treatment.
"Our AAIC presentations reflect more than a decade of disciplined execution in addressing one of the most urgent global unmet needs: Alzheimer's disease (搜索) in APOE4 (搜索)/4 patients, who carry the greatest genetic risk and are most vulnerable to complications from anti-amyloid antibodies," said Martin Tolar, MD, PhD, Founder, President and CEO of Alzheon. "Across nine presentations covering Phase 3 efficacy and safety, imaging and plasma biomarkers, long-term safety, and a new analysis of valiltramiprosate as a potential oral maintenance therapy after anti-amyloid antibody treatment, we are positioning valiltramiprosate as a foundational oral therapy and strengthening Alzheon's precision medicine platform."
Mechanism of Action and Target Population
Valiltramiprosate is an investigational oral agent in Phase 3 development as a potential first-in-class, disease-modifying treatment for Alzheimer's disease (搜索). It acts upstream of anti-amyloid antibodies by inhibiting the formation of neurotoxic soluble amyloid oligomers (搜索). Preclinical mechanism-of-action studies have demonstrated that ALZ-801 can completely block the formation of these neurotoxic oligomers at the dosage used in Phase 3 clinical trials. The Phase 3 program targets patients with mild cognitive impairment (MCI) who are homozygous for the apolipoprotein ε4 allele (APOE4 (搜索)/4), a group that represents approximately 15% of all Alzheimer's patients.
Because APOE4 (搜索)/4 Alzheimer's patients have a high prevalence of cerebral amyloid angiopathy (搜索) (CAA), they are particularly vulnerable to brain edema and microhemorrhage complications associated with anti-amyloid antibody therapies, known as amyloid-related imaging abnormalities (ARIA). The AAIC presentations will report neurovascular and ARIA outcomes from the placebo-controlled APOLLOE4 trial. These findings may also have implications for treating CAA patients and adults with Down syndrome, who similarly have a high prevalence of underlying CAA.
Phase 3 and Long-Term Extension Findings
Although the Phase 3 APOLLOE4 trial did not meet its primary endpoint, the new analyses being presented at AAIC reinforce valiltramiprosate's differentiated profile. "The expanded Phase 3 analyses showed consistent neurovascular protection, including lower ARIA rates in the overall population versus placebo, together with clinically meaningful benefits on cognition and brain volume in the pre-specified MCI subgroup from the Phase 3 and Phase 2 long-term extension studies," said Susan Abushakra, MD, Chief Medical Officer of Alzheon.
New DTI analyses further demonstrated preservation of hippocampal microstructure and correlations with clinical and brain volume outcomes. Dr. Abushakra noted that these structural effects, together with a significant reduction in plasma p-tau217 (搜索) in the overall population, support the disease-modifying potential of valiltramiprosate. Importantly, long-term extension findings in APOE4 (搜索)/4 and APOE3/4 carriers continue to show a favorable safety profile, with no symptomatic ARIA-E or ARIA-H observed through up to four years of treatment.
Trial Design and Dosing
The APOLLOE4 Phase 3 trial (NCT04770220) was a double-blind, randomized study comparing oral valiltramiprosate 265 mg twice daily to placebo over 78 weeks in Early AD subjects with two copies of the APOE4 (搜索) allele. The trial was supported by a grant from the National Institute on Aging, with Susan Abushakra as the principal investigator. The APOLLOE4 long-term extension (NCT06304883) evaluated valiltramiprosate for an additional 104 weeks, totaling 182 weeks or 3.5 years of treatment, and ended in January 2026.
The Phase 2 biomarker trial (NCT04693520) evaluated the same 265 mg twice daily dose in APOE4 (搜索)/4 and APOE3/4 carriers, who constitute 65-70% of Alzheimer's patients, with a primary outcome of change from baseline in plasma p-tau181 over 104 weeks. Its long-term extension evaluated treatment for an additional 104 weeks, totaling 208 weeks.
AAIC 2026 Presentation Schedule
The nine posters span four days of the conference. On Sunday, July 12, presentations will cover correlations between microstructure and efficacy/brain atrophy, and valiltramiprosate's effects on plasma p-tau217 (搜索) and vMRI. Monday, July 13, features posters on reduced ARIA rates, hippocampal microstructure improvements, and sustained CDR-SB benefit over 2.5 years in the MCI subgroup. Tuesday, July 14, includes safety data through four years, clinical stability and slowed atrophy over four years, and cerebellar volume effects. On Wednesday, July 15, a QSP analysis will evaluate valiltramiprosate as oral maintenance therapy following donanemab or lecanemab treatment.
Valiltramiprosate received Fast Track designation from the U.S. Food and Drug Administration in 2017 for the treatment of Alzheimer's disease (搜索). If approved, it could become the first oral therapy to slow Alzheimer's pathology.